New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT06737731
Summary
This early-stage clinical trial is testing a new drug called SHR-1681 in patients with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest and most effective dose, understand how the drug moves through the body, and see if it helps control cancer. About 300 participants with various types of solid tumors will receive the experimental injection to help researchers gather initial safety and effectiveness data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Dongfang Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.